Biosimilar Red Tape Elimination Act
Senate Bill Would Make Biosimilars Automatically Interchangeable, Cutting Drug Switching Red Tape
Stalled
No legislative action in over 90 days.
Legislative Progress
Key Points
- This bill would treat most approved biosimilar medicines as automatically interchangeable with the original biologic drug.
- That could make it easier for pharmacies and health plans to switch to a lower-cost biosimilar, similar to how generics work for many drugs.
- It sets a transition: new biosimilars would be interchangeable right away after approval, and older approved biosimilars would become interchangeable 60 days after the bill becomes law.
- It keeps certain temporary exclusivity protections already in place, so automatic interchangeability could be delayed when a protected product is still in its exclusivity window.
- It requires the federal health agency to update and revise its biosimilar guidance documents within 18 months to match the new rules.
Impact Analysis
Personal Impact
How this policy affects specific groups of people
Milestones
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in Senate
The bill was officially filed and given a number. It now enters the legislative queue.
Votes
No votes have been recorded for this legislation yet.
Related News
4 articlesSenate HELP Committee chair pitches proposals for FDA reform
Senate HELP Committee Chair Bill Cassidy released a report proposing reforms to the FDA review process, including codifying the agency's stance that all approved biosimilars should be considered interchangeable. The report aligns with the goals of the Biosimilar Red Tape Elimination Act.
Biosimilar Red Tape Elimination Act (S.2305): weakening FDA regulatory standards for biosimilars, undermining physician confidence and jeopardizing patient health
This report examines the potential risks of the Biosimilar Red Tape Elimination Act, noting that classifying all biosimilars as interchangeable without switching studies could weaken FDA standards and undermine physician confidence in pharmacy-level substitutions.
Senator Reintroduces Biosimilar Red Tape Elimination Act
Senator Mike Lee reintroduced the Biosimilar Red Tape Elimination Act to end switching study requirements for companies seeking interchangeability designations. The bill would amend federal code to state that all biosimilars are deemed interchangeable upon initial FDA approval.
Source Information
Document Type
Congressional Bill
Official Title
Biosimilar Red Tape Elimination Act
Data Sources
Sponsor
Cosponsors
(4)Analysis generated by AI. Always verify with official sources.